Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital

Journal of Medical Investigation

Volumn 58, Issue 3-4, 2011, Pages 219-226

  Goto, Hisatsugu ^a   Hanibuchi, Masaki ^a   Sakaguchi, Satoshi ^a   Kanematsu, Takanori ^a   Kakiuchi, Soji ^a   Tomimoto, Hideki ^a   Azuma, Masahiko ^a   Tezuka, Toshifumi ^a   Tada, Hiroya ^a   Miki, Yukiyo ^b   Nakamura, Toshimi ^b   Sone, Saburo ^a   Nishioka, Yasuhiko ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Best overall response; Lung cancer; Outpatient chemotherapy; Time to treatment failure

Indexed keywords

AMRUBICIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HYPONATREMIA; INFECTION; JAPAN; LEUKOPENIA; LUNG CANCER; LUNG DISEASE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTPATIENT CARE; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 80052747298     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.58.219     Document Type: Article

References (19)

1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statisitics, 2000. CA Cancer J Clin 50: 7-30,2000
2. Bunn PA Jr, Thatcher N: Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion. Oncologist 13(Suppl 1): 37-46, 2008
3. Scalamonga R, Brugnatelli S, Tinelli C, Sagrada P, Gattoni E, Tronconi MC, Riccardi A, Luchena G, Corazza GR: UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. Oncology 72 (5-6): 267-273, 2008
4. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH; Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002
5. Lynch TJ Jr: Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer. Semin Oncol 28(Suppl 9): 5-9, 2001
6. Thatcher N: First and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view. BMC Proc 2(Suppl 2): S3-S8, 2008
7. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000
9. Tan EH, Rolski J, Grodzki T, Schneider CP, Gatzemeier U, Zatloukal P, Aitini E, Carteni G, Riska H, Tsai YH, Abratt R: Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as firstline treatment of advanced non-small-cell lung cancer. Ann Oncol 20(7): 1249-1256, 2009
10. Travis WD: Histological typing of lung cancer and pleural tumours. WHO International Histological Classification of Tumours. 3rd ed., Springer, Berlin, 1999
11. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N.; Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346: 85-91, 2002
12. Park JO, Kim SW, Ahn JS, Suh C, Lee JS, Jang JS, Cho EK, Yang SH, Choi JH, Heo DS, Park SY, Shin SW, Ahn MJ, Lee JS, Yun YH, Lee JW, Park K: Phase III trial of two versus four additional cycles in patients who are non-progressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 25: 5233-5239, 2007
13. Majem M, Galán M, Pérez FJ, Muñoz M, Chicote S, Soler G, Navarro M, Martínez-Villacampa M, García del Muro X, Dotor E, Laquente B, Germà JR: The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity. Clin Transl Oncol 9: 784-788, 2007
14. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M: Randomized phase III study of cisplatin plus irinotecan versus car-boplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323, 2007
15. Ramalingam S, Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 13(Suppl 1): 5-13, 2008
16. Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F, Herbst RS: A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39: 55-61, 2003
17. Silvestri G, Pritchard R, Welch HG.: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317: 771-775, 1998
18. Dubey S, Brown RL, Esmond SL, Bowers BJ, Healy JM, Schiller JH: Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. J Support Oncol 3:149-154,2005
19. Coory M, Gkolia P, Yang IA, Bowman RV, Fong KM: Systematic review of multidisciplinary teams in the management of lung cancer. Lung Cancer 60: 14-21, 2008